Related Experiment Video
Updated: Nov 5, 2025

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia
Published on: December 19, 2020
Severe COVID-19: A distinct entity
Ravindra Kumar Garg1, Gyan Prakash Singh2, Rajiv Garg3
1Department of Neurology, King George Medical University, Lucknow, Uttar Pradesh, India.
Insights
Severe coronavirus disease-2019 (COVID-19) can rapidly progress to critical illness, particularly in older men with comorbidities. Current treatments lack efficacy, highlighting the need for supportive care and mechanical ventilation for severe COVID-19 patients.
Area of Science:
- Critical care medicine
- Infectious diseases
- Pulmonology
Background:
- Severe coronavirus disease-2019 (COVID-19) is a distinct clinical entity.
- Approximately 15% of COVID-19 patients develop severe disease, and 5% become critically ill.
- Risk factors include male sex, age over 65, and comorbidities.
Purpose of the Study:
- To describe the characteristics and outcomes of severe and critical COVID-19.
- To identify key pathophysiological mechanisms in severe COVID-19.
- To outline management strategies for severe and critical COVID-19.
Main Methods:
- Observational study based on Chinese experience.
- Analysis of clinical data from severe and critical COVID-19 patients.
- Review of existing literature on COVID-19 pathophysiology and treatment.
Main Results:
- Cytokine storm leads to lung damage and multiorgan failure.
- Coagulopathy and thromboembolism are common in critical illness.
- Lymphopenia is associated with severe disease.
- No antiviral or immunomodulator has proven efficacy.
- Hypoxemia requires supplemental oxygen; ARDS, encephalopathy, and organ failure necessitate mechanical ventilation.
Conclusions:
- Severe COVID-19 has a poor prognosis in many patients.
- Management focuses on supportive care, oxygen therapy, and mechanical ventilation.
- Healthcare workers face significant risk of SARS-CoV-2 infection in intensive care units.
Abstract:
Severe coronavirus disease-2019 (COVID-19) is a distinct entity that rapidly evolves and may abruptly culminate in to a critical illness. As per Chinese experience, approximately, 15% of patients of COVID-19 progress to severe disease and 5% become critically ill. The incidence of severe and critical illness is higher among men, patients older than 65 years of age and in persons with other medical comorbidities. Cytokine storm cause pronounced lung damage and multiorgan failure. Coagulopathy is a key component of severe COVID-19. Critically ill patients are generally predisposed to a high risk of thromboembolism as well. Lymphopenia predisposes to severe disease. None of the antiviral or immunomodulators has proven efficacy in severe COVID-19. Supplemental oxygen need be administered in patients with hypoxemia. Excessive breathing effort, acute respiratory distress syndrome (ARDS), encephalopathy, and multiorgan failure are indications for mechanical ventilation. In a large number of patients, the overall outcome is poor. Health care workers in intensive care units are exposed to the enormous risk of acquiring hospital acquired SARS-COV-2 infection.
More Related Videos
Related Concept Videos
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Endocarditis II: Clinical Features of Infective Endocarditis
Coronary Artery Disease III: Clinical Manifestations
Pneumonia II: Pathophysiology
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Myocarditis II: Clinical Features and Diagnostic Tests

